Breye Therapeutics

Breye Therapeutics develops oral medicines for retinal diseases, with a focus on diabetic retinopathy and age-related macular degeneration.

Health and bio

Breye Therapeutics raised $67.5M in a Series A round announced September 29, 2026, according to european-biotechnology.com. Investors in that round: Mission BioCapital, Novo Holdings, Catalyze Capital, Export and Investment Fund, Innovestor, Modi Ventures, Pappas Capital, Sound Bioventures, The Ljungstrom Family Office.

Founders and team

• UM
  Ulrik Mouritzen Founder

  source: crunchbase.com
• JV
  Jim Van heusden Board member

  source: crunchbase.com
• JK
  Johan Kördel Board member

  source: crunchbase.com
• JS
  Jørgen Søberg Petersen Board member

  source: crunchbase.com
• LL
  Lukas Ljungstrom Board member

  source: crunchbase.com
• RB
  Robert Blazej Board member

  source: crunchbase.com

Raise history

1. September 29, 2026
   Series A · $67.5M
   MMission BioCapital (lead), NNovo Holdings (lead), CCatalyze Capital, EExport and Investment Fund, IInnovestor, MModi Ventures, PPappas Capital, SSound Bioventures, TThe Ljungstrom Family Office
   Source: european-biotechnology.com
2. May 4, 2005
   Website created

Investors

• CCatalyze Capital
• EExport and Investment Fund
• IInnovestor
• MMission BioCapital
• MModi Ventures
• NNovo Holdings
• PPappas Capital
• SSound Bioventures
• TThe Ljungstrom Family Office
• VVaekstfonden

Related bio health companies

• TTriGemX Bio$94M · Oct 1, 2026
• SSedMed$4M · Oct 1, 2026
• SSharp$328K · Oct 1, 2026
• MM-BasedOct 1, 2026
• AAyna HealthOct 1, 2026
• BBiotia$9M · Oct 1, 2026
• RR1 Therapeutics$80.5M · Sep 30, 2026
• LLinux Laboratories$70M · Sep 30, 2026

Every amount links to the page it came from. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/breye-therapeutics.